COVID-19 Update

Our primary concern is the safety of all our study participants and minimising any additional strain on our clinical sites and staff.

The COVID-19 pandemic is affecting people and health services around the world. Our primary concern is the safety of all our study participants and minimising any additional strain on our clinical sites and staff. We are working closely with our clinical sites and partner organisations to find ways of doing this. Please contact the relevant trial team via the trial email address if you have questions about what this means for a specific study.

We are working on developing several studies looking at COVID-19, including the ACTT- EU/UK trial. We hope to open this study in April 2020. It will test drugs to treat people in hospital due to the virus. The adaptive design will allow us to add new treatment comparisons as new potential ways to treat the disease are discovered.

Latest News and Updates

Active surveillance after surgery still best approach for kidney cancer

Results from the SORCE trial confirm that the drug sorafenib should not be used as treatment straight after surgery for kidney cancer. These results were published yesterday in the Journal of Clinical Oncology.

15 Oct

Men who have had prostate cancer surgery do not need immediate radiotherapy

These results are good news for the 7,000 men who are treated for prostate cancer by radical prostatectomy each year.

29 Sep

Weekly chemotherapy does not improve ovarian cancer survival compared to three-weekly chemotherapy

Long-term follow-up results of the ICON8 trial have shown that having chemotherapy every week does not improve survival for women with ovarian cancer compared to having it once every three weeks, as has been standard for…

22 Sep

Data from ODYSSEY increases treatment options for older children living with HIV

Results from a sub-study of the ODYSSEY trial, published today in The Lancet HIV journal, show that children over 20kg in weight can safely have adult doses (50mg) of the anti-HIV drug dolutegravir.

05 Aug

Our Research Themes

Cancer

Innovative clinical trial design and meta-analysis extending beyond the boundaries of single cancer types

Infections

Major international clinical trials answering questions of global public health significance

Methodology

Development of methods with direct impact on the design, conduct and analysis of studies

Other Research & Policy

This section will capture projects outside the current QQR themes

Our Latest Tweets

MRC CTU at UCL MRCCTU

Reference‐based multiple imputation for missing data sensitivity analyses in trial‐based cost‐effectiveness analysis. Read it free here 🔓: https://t.co/GyKaVZJZ9f #MultipleImputation #MissingData #StatsTwitter #ClinicalTrials https://t.co/6IL5mUJ5JB

Oct 23
MRC CTU at UCL MRCCTU

#Publication - Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. Read for free here 🔓: https://t.co/32nWLRKRev #MAMS #AdaptiveTrials #PlatformTrials #COVID19 #MetaAnalysis @trials_doc @mattsydes https://t.co/EqhU7bjUTd

Oct 22
MRC CTU at UCL MRCCTU

RT @Penta_ID: Congratulations to Professor Sarah Walker - a key investigator in Penta ID network. She's been made 'Officer of the Order of…

Oct 22